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Background: Achieving stable closure of complex or contaminated abdominal wall incisions remains
challenging. This study aimed to characterize the stage of innovation for biological mesh devices used
during complex abdominal wall reconstruction and to evaluate the quality of current evidence.
Methods: A systematic reviewwas performed of published and ongoing studies between January 2000 and
September 2017. Eligible studies were those where a biological mesh was used to support fascial closure,
either prophylactically after midline laparotomy, or for reinforcement after repair of incisional hernia with
midline incision. The primary outcome measure was the IDEAL framework stage of innovation. The key
secondary outcome measure was the GRADE criteria for study quality.
Results: Thirty-five studies including 2681 patients were included. Four studies considered mesh pro-
phylaxis, 23 considered hernia repair, and eight reported on both. There was one published randomized
trial (IDEAL stage 3), none of which was of high quality; the others were non-randomized studies (IDEAL
stage 2a). A detailed description of surgical technique was provided in most studies (27 of 35); however,
no study reported outcomes according to the European Hernia Society consensus statement and only
two described quality control of surgical technique during the study. From 21 ongoing randomized trials
and observational studies, 11 considered repair of incisional hernia and 10 considered prophylaxis (seven
in elective settings).
Conclusion: The evidence base for biological mesh is limited, and better reporting and quality control
of surgical techniques are needed. Although results of ongoing trials over the next decade will improve
the evidence base, further study is required in the emergency and contaminated settings.
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Introduction
Incisional hernias carry a significant burden for both
patients and the health service1–4. They prevent return to
normal activities and can be painful. Elective repair can be
challenging, and emergency repair carries significant clin-
ical risks. Incisional hernia is common, occurring in up to
50 per cent of patients after laparotomy5,6, and with the
growing number of emergency laparotomies performed
in the UK, the number of affected patients is likely to
increase7.
To limit the number of incisional hernias there has been a
focus on the use of prophylactic mesh reinforcement. The
cost of mesh is far less than that of major reoperations and
emergency admissions3,8–10. Although synthetic meshes
are accepted in many cases, they are not used in complex
and contaminated settings owing to the risk of infection
(as high as 50–90 per cent), pain, fistulation and need for
explantation11–14. Biological mesh has evolved to fill this
gap, with expected reduced rates of infection leading to
safer prophylaxis. Current guidelines, including the Ven-
tral Hernia Working Group expert consensus, and several
systematic reviews recommend against the use of synthetic
mesh when the risk of wound complications is high, such
as in the presence of gross contamination; instead they
advocate the use of a biological absorbable mesh15–17.
© 2018 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd BJS Open 2018; 2: 371–380
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
372 S. K. Kamarajah, S. J. Chapman, J. Glaseby, D. Morton, N. Smart, T. Pinkney and A. Bhangu
Biological mesh has entered widespread clinical prac-
tice, but the quality and scope of the evidence base for
use in complex and contaminated abdominal wounds are
unclear. This review aimed to determine the quality and
stage of innovation of the evidence supporting biological
mesh placement during abdominal wall reconstruction
with primary fascial closure. The hypothesis was that the
evidence base supporting biological mesh use is currently
too limited to support routine clinical use outside clinical
trials.
Methods
Search strategy
A systematic search of PubMed, EMBASE and the
Cochrane Library between 1 January 2000 and 27 Septem-
ber 2017 was performed by two independent investigators.
The ClinicalTrials.gov database was also queried for on-
going studies. The search terms used were ‘laparotomy’,
‘mesh’, ‘biologic material’, ‘abdominal wall’, ‘hernia’, and
‘complications’, ‘contamination’, ‘infection’ or ‘surgical
site infection’, individually or in combination. The ‘related
articles’ function was used to broaden the search, and all
citations were considered for relevance. A manual search
of reference lists in recent reviews and eligible studies was
also undertaken. This paper is reported according to the
PRISMA guidelines18.
Inclusion and exclusion criteria
Studies were included according to the following criteria:
evaluation of the use of a xenograft biological mesh to sup-
port primary fascial closure of midline abdominal wounds
or repair of incisional hernia with midline incision; study
design was an RCT, prospective observational study, retro-
spective cohort study or case series; study included only
patients aged 16 years or more.
The following exclusion criteria were employed: study
design was a systematic review, meta-analysis, letter,
review, comment or conference abstract; fewer than five
patients were included in the study; only synthetic mesh
or composite meshes were evaluated; allograft or autograft
meshes, including human-derived acellular dermal matrix,
were used (availability in Europe across the selected inclu-
sion dates was low until recently, so reporting is likely to
be incomplete); study reported bridging repairs (fascial
closure not achieved), including studies where outcomes
for fascial closure were not reported separately from
bridging repair.
Study outcome measures
The primary outcome measure was the stage of innova-
tion, according to the IDEAL framework19. The level of
evidence in the IDEAL staging system were 1 (case series
with high risk of bias), 2a (cohort study), 2b (feasibility
RCT), 3 (RCT) and 4 (high-quality prospective registry
with long-termmonitoring and low risk of bias). All assess-
ments in the present study were carried out independently
by two authors; disagreement was resolved by re-examining
the relevant article until consensus was achieved.
Secondary outcome measures
The main secondary outcome measure was the quality
of evidence assessed using the GRADE system20. In the
GRADE approach, studies are categorized as of high
(randomized trials or double-upgraded observational
studies), moderate (downgraded randomized trials or
upgraded observational studies), low (double-downgraded
randomized trials or observational studies) and very low
(triple-downgraded randomized trials, downgraded obser-
vational studies or case series/case reports) quality. The
other secondary outcome measures of interest were the
numbers of studies reporting: outcomes according to the
European Hernia Society consensus statement21, inci-
dence of incisional hernia, surgical-site infection (SSI)
rate, and seroma.
Data extraction
Data extracted included patient demographics, indica-
tions and type of biological mesh used. Studies were
grouped into those examining prophylactic placement in
primary closure of laparotomy only (prophylaxis), repair
of incisional hernia only (reinforcement), or both (mixed).
Descriptions of procedures performed were collected,
including surgical technique, number of procedures pre-
viously performed by the surgeon, and monitoring of
technique. Degree of contamination (clean-contaminated,
contaminated or dirty surgery) was defined according
to the US Centers for Disease Control and Prevention
(CDC) surgical wounds classification22, and the loca-
tion of biological mesh placement was also evaluated,
as either intraperitoneal (intraperitoneal, intraperitoneal
onlay mesh, underlay, intra-abdominal) or extraperi-
toneal (sublay, onlay, inlay, retromuscular, retrorectus,
prefascial)23.
Statistical analysis
Analysis was intended to be primarily descriptive in nature,
with no need formodelling ormultivariable analyses. Event
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Fig. 1 PRISMA diagram for the study
rates are reported as percentages. Continuous variables
were tested for normality.
Results
Of 1304 studies shortlisted, 35 full-text articles24–58 met
the inclusion criteria (Fig. 1). Of these, four examined bio-
logical mesh for prophylaxis, 23 reported on reinforcement
after incisional hernia repair, and eight reported both pro-
phylaxis and incisional hernia repair. Studies of biological
mesh for prophylaxis included a total of 85 patients with a
median follow-up of 12 (i.q.r. 2–31) months; those used
for reinforcement included 1744 patients with a median
follow-up of 16 (12–24) months, and those for mixed indi-
cations included 852 patients with a median follow-up of
24 (17–48) months.
Mesh characteristics
Tables 1 and 2 summarize characteristics of the included
studies. Strattice™ (KCIMedical, Dublin, Ireland) (2 stud-
ies), Surgisis® (Cook Biotech, West Lafayette, Indiana,
USA) (1 study) and bovine pericardium (1) were used
for prophylaxis in abdominal wound reconstruction. For
reinforcement, Permacol™ (Tissue Science Laboratories,
Andover, Massachusetts, USA) (9 studies) was the most
commonly used mesh, followed by Strattice™ (4) and
Surgisis® (3); a further seven studies each used different
meshes. In papers reportingmixed indications, Permacol™
(5 studies) was the most commonly reported, followed
by XenMatrix™ (Brennen Medical, St Paul, Minnesota,
USA; Davol,Warwick, Rhode Island, USA) (1), Strattice™
(1) and SurgiMend™ (TEI Biosciences, Boston, Massa-
chusetts, USA) (1).
IDEAL stage of innovation and GRADE quality
of evidence
Distribution of IDEAL stage and GRADE quality of
included studies are presented in Tables 3 and 4 respec-
tively. Of the four prophylaxis studies, two24,25 evaluated
biological mesh at the time of stoma closure, one26
following midline laparotomy after abdominal aortic
aneurysm (AAA) repair, and one27 after cytoreduction
and hyperthermic intraperitoneal chemotherapy. All four
studies included only elective patients and the degrees of
contamination were clean-contaminated (2) and contami-
nated (2). Strattice™ was used in two studies24,25 with an
intraperitoneal placement; the others used bovine peri-
cardium in an extraperitoneal position (1)26 or Surgisis® in
an intraperitoneal position (1)27. One study24 was IDEAL
stage 2a (low quality) and the other26 was IDEAL stage
3 (moderate quality). Two studies25,27 reported only out-
comes of patients with biological mesh; both studies were
IDEAL stage 2a (very low quality).
Of the 23 studies28–50 using biological mesh for rein-
forcement, all reported only elective patients undergoing
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Table 1 Patient characteristics (arranged alphabetically by timing of surgery)
Reference
No. of
patients
Median age
(years)
Mean
BMI (kg/m2)
Timing
of surgery* Indication for surgery
Bali et al.26 40 75 25 Elective AAA repair
Bhangu et al.25 7 9 n.a. Elective Stoma closure
Boules et al.49 45 57 33 Elective Incisional hernia repair
Boutros et al.27 8 60 n.a. Elective AWR after HIPEC
Chamieh et al.31 58 n.a. n.a. Elective Incisional hernia repair
Chavarriaga et al.32 18 49 n.a. Elective Incisional hernia repair
Cheng et al.28 270 60 32 Elective Incisional hernia repair
Cox et al.48 6 49 25 Elective Incisional hernia repair
Fayezizadeh et al.33 77 56 35 Elective Incisional hernia repair
Garvey et al.52 191 58 31 Elective AWR, incisional hernia repair
Giordano et al.47 109 64 30 Elective Incisional hernia repair
Giordano et al.53 484 59 31 Elective Data not available
Gnaneswaran et al.50 12 51 32 Elective Incisional hernia repair
Hicks et al.34 60 59 36 Elective Incisional hernia repair
Høyrup et al.57 10 66 n.a. Elective Incisional hernia repair, stoma closure, left
hemicolectomy, anterior resection, bowel
obstruction
Hsu et al.35 28 55 34 Elective Incisional hernia repair
Itani et al.36 80 57 n.a. Elective Incisional hernia repair
Limpert et al.37 26 54 n.a. Elective Incisional hernia repair
Madani et al.38 46 58 28 Elective Incisional hernia repair
Maggiori et al.24 30 61 26 Elective Stoma closure
Majumder et al.39 126 59 37 Elective Incisional hernia repair
Nockolds et al.40 23 57 n.a. Elective Incisional hernia repair
O’Halloran et al.41 85 56 33 Elective Incisional hernia repair
Patel et al.42 41 42 20 Elective Incisional hernia repair
Rosen et al.43 128 58 34 Elective Incisional hernia repair
Sbitany et al.44 41 66 25 Elective Incisional hernia repair
Shah et al.45 58 57 34 Elective Incisional hernia repair
Shaikh et al.56 20 51 n.a. Elective Incisional hernia repair, re-exploration laparotomy,
multiple stab wounds, desmoid tumour
resection
Ueno et al.29 20 60 n.a. Elective Incisional hernia repair
Warwick et al.30 57 64 30 Elective Incisional hernia repair
Zerbib et al.46 14 60 35 Elective Incisional hernia repair
Abdelfatah et al.58 65 55 35 Mixed Incisional hernia repair, intestinal obstruction
(bowel strangulation and resection), resection
of large section abdominal wall, infected
alloplastic mesh
Byrnes et al.51 57 49 32 Mixed Incisional hernia repair, trauma laparotomy
Parker et al.54 9 58 n.a. Mixed Incisional hernia repair, AWR for abdominal wall
tumour
Pomahac and Aflaki55 16 59 28 Mixed Incisional hernia repair, intra-abdominal
emergencies, extensive bowel resection,
abdominal compartment syndrome secondary
to necrotizing fasciitis
*Mixed indicates both elective and emergency surgery. AAA, abdominal aortic aneurysm; AWR, abdominal wall reconstruction; HIPEC, hyperthermic
intraperitoneal chemotherapy.
repair of incisional hernia. The degree of contamination
in all studies was clean-contaminated. Mesh placement
was reported as intraperitoneal in five studies34,35,42,44,46,
extraperitoneal in seven30,32,33,37,40,48,50 and a combination
in ten studies29,31,36,38,39,41,43,45,47,49. One study28 did not
report the location of mesh placement. Four30,31,39,41
of the 23 studies compared biological versus synthetic
mesh. All 23 studies were IDEAL stage 2a (cohort
studies). Seven29,31,38,40,48–50 were of very low quality,
1430,32–37,39,42–47 of low quality, and two28,41 of moderate
quality. None reported standardization of technique or
location of biological mesh placement; the choice of mesh
type was based on the preference of operating surgeon.
Of the eight studies evaluating biological mesh for mixed
indications, four included patients undergoing elective
surgery and the remaining four studies included both
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Table 2 Summary of surgery and mesh characteristics (arranged chronologically by indication)
Reference Year Country Indication Type of mesh Median follow-up (months)
Boutros et al.27 2010 USA Prophylaxis Surgisis® 6
Bhangu et al.25 2014 UK Prophylaxis Strattice™ 1
Bali et al.26 2015 Greece Prophylaxis Bovine pericardium 36
Maggiori et al.24 2015 France Prophylaxis Strattice™ 17
Ueno et al.29 2004 USA Reinforcement Surgisis® 16
Limpert et al.37 2009 USA Reinforcement Bovine pericardium 22
Hsu et al.35 2009 USA Reinforcement Permacol™ 16
Chavarriaga et al.32 2010 USA Reinforcement Permacol™ 7
Cox et al.48 2010 USA Reinforcement Surgisis® 10
Shah et al.45 2011 USA Reinforcement XenMatrix™ 12
Patel et al.42 2012 USA Reinforcement Strattice™ 16
Itani et al.36 2012 USA Reinforcement Strattice™ 24
Rosen et al.43 2013 USA Reinforcement Strattice™ 22
Nockolds et al.40 2014 UK Reinforcement Permacol™ 17
Cheng et al.28 2014 USA Reinforcement Permacol™/Strattice™ 25
O’Halloran et al.41 2014 USA Reinforcement Unknown 14
Zerbib et al.46 2015 France Reinforcement Permacol™ 13
Giordano et al.47 2015 UK Reinforcement Permacol™ 24
Sbitany et al.44 2015 USA Reinforcement Strattice™ 5
Gnaneswaran et al.50 2016 Australia Reinforcement BioDesign® 14
Fayezizadeh et al.33 2016 USA Reinforcement Permacol™ 28
Majumder et al.39 2016 USA Reinforcement Permacol™ 22
Hicks et al.34 2016 USA Reinforcement SurgiMend™ 12
Warwick et al.30 2017 UK Reinforcement Permacol™ 18
Madani et al.38 2017 Canada Reinforcement Surgisis® 47
Chamieh et al.31 2017 USA Reinforcement Mixed 11
Boules et al.49 2018 USA Reinforcement Permacol™ 72
Parker et al.54 2006 USA Mixed Permacol™ 18
Shaikh et al.56 2007 Ireland Mixed Permacol™ 18
Pomahac and Aflaki55 2010 USA Mixed Permacol™ 17
Byrnes et al.51 2011 USA Mixed XenMatrix™ 31
Høyrup et al.57 2012 Denmark Mixed Permacol™ 8
Abdelfatah et al.58 2015 USA Mixed Permacol™ 60
Garvey et al.52 2017 USA Mixed Strattice™ 53
Giordano et al.53 2017 USA Mixed SurgiMend™ 31
Table 3 Distribution of IDEAL stage of innovation, by indication
IDEAL stage
Indication
1 (case
report)
2a (cohort
study)
2b (feasibility
RCT)
3
(RCT)
4
(registry)
Total (n=35) 0 34 0 1 0
Prophylaxis (n=4) 0 3 0 1 0
Reinforcement (n=23) 0 23 0 0 0
Mixed (n=8) 0 8 0 0 0
elective and emergency operations. The eight studies
involved a mixture of procedures, with degree of con-
tamination ranging from clean-contaminated to dirty.
Mesh placement was intraperitoneal in six studies51–56,
extraperitoneal in one study57, and a combination in
one study58. All were IDEAL stage 2a (cohort studies).
Evidence was of very low quality in three studies54,56,57,
low quality in three51,52,55, and moderate quality in
two53,58. The evidence in one study58 of abdominal wall
Table 4 Distribution of GRADE study quality, by indication
GRADE quality
Indication High Moderate Low Very low
Total (n=35) 0 5 18 12
Prophylaxis (n=4) 0 1 1 2
Reinforcement (n=23) 0 2 14 7
Mixed (n=8) 0 2 3 3
reconstruction with porcine acellular dermal matrix
(Permacol™) was of moderate quality owing to reporting
of long-term outcomes of at least 5 years.
Outcome reporting
None of the studies in this review reported outcomes
according to the European Hernia Society consensus
statement21, and none reported ‘free from hernia’ survival
times. All four studies24–27 in the prophylaxis group
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reported a definition for detection of incisional hernia,
which included a combination of clinical examination
and radiological assessment. In the reinforcement group,
1329,30,32,33,35,36,38,39,41–44,47 of the 23 studies gave a defi-
nition for recurrence of hernia (6 clinical, 7 radiological,
none patient-reported). SSI rates were reported in one25
of the four studies in the prophylaxis group, and in 21
of the 23 studies in the reinforcement group. The inci-
dence of seroma was reported in three prophylaxis and 19
reinforcement studies.
Reporting of surgical technique
Of the 35 studies, 27 provided details of surgical pro-
cedures: all four studies in the prophylaxis group, 16 in
the reinforcement group, and seven in the mixed group
(Table 5). Only one paper46 reported the minimum number
of procedures performed by the operating surgeons as a
requirement.
Ongoing studies
Twenty-one ongoing studies were identified from
ClinicalTrials.gov, of which ten were for prophylaxis
Table 5 Reporting of surgical technique
All
indications*
Prophylaxis
only
Reinforcement
only
No. of studies 35 4 23
Total no. of patients 2681 85 1744
Mesh type
BioDesign® 1 0 1
Bovine pericardium 2 1 1
Mixed 1 0 1
Permacol™ 12 0 9
Permacol™/Strattice™ 1 0 1
Strattice™ 7 2 4
SurgiMend™ 2 0 1
Surgisis® 4 1 3
XenMatrix™ 3 0 2
n.r. 1 0 1
Location of mesh placement
Intraperitoneal
(intraperitoneal underlay)
14 3 5
Extraperitoneal (sublay,
onlay, inlay)
9 1 7
Mixed (intraperitoneal and
extraperitoneal)
11 0 10
n.r. 1 0 1
Description of procedure
Detailed surgical technique
provided
27 4 16
Surgeon’s no. of previous
procedures provided
1 0 1
Monitoring of technique 2 0 2
*Includes prophylaxis only, reinforcement only, and mixed. n.r., Not
reported.
and 11 for reinforcement. In the prophylaxis group, all
were RCTs; four had completed data collection, five were
still recruiting, and one had terminated early. Patient
groups being studied included emergency midline laparo-
tomy (1 study), elective patients for AAA repair (1), midline
laparotomy (1), contaminated abdominal wall defect (1,
terminated), abdominoperineal resection (1) and stoma
closure (5). Of these ten, the majority studied Strattice™
(4), followed by Permacol™ (1) and Surgisis® (1). The type
of biological mesh was not mentioned in the remaining
four studies. In the 11 ongoing trials of reinforcement, nine
were RCTs and two were cohort studies. Two studies (1
cohort study of Permacol™ and 1 RCT of XenMatrix™)
were in follow-up phase; the remainder were still recruiting
patients.
Discussion
This review identified that the evidence base for biological
mesh in complex and contaminated settings is still evolv-
ing, and highlighted areas for improvement. At present,
the quality of the evidence base is generally low, with a few
exceptions. The majority of studies included in this review
were IDEAL stage 1 or 2 (case series or cohort studies) with
a low or very low GRADE quality of evidence, indicating
that biological meshes remain in the early stages of eval-
uation and adoption. This is compounded by a wide vari-
ation in mesh types and mesh placement, with little con-
trol for surgical technique, making synthesis of evidence
ineffective.
There are two key recommendations from the present
study. First, the evidence base needs to be improved by
testing the efficacy of biological mesh in randomized tri-
als. This should include standardization of techniques and
reporting, and inclusion of more emergency cases to estab-
lish the limits of indication. Second, future studies should
allow consistent reporting of mesh type and exact place-
ment to enable high-quality recommendations to help
standardize practice. Until such data are available, use in
selected higher-risk patients (such as prophylaxis during
abdominal wall closure in contaminated cases at high risk
of incisional hernia) should be supported by data capture
within controlled trials or registries. Routine clinical use in
low-risk patients is not yet justified.
Surgeons and patients will benefit from knowing about
mesh performance based on the specific type of mesh,
the position it is placed in, and the expected long-term
outcome. The present study identified variation in out-
come reporting for recurrence rates, SSI and seroma. This
variation precludes reliable assessment of outcomes and
formation of recommendations. Recently, Blencowe and
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colleagues59 proposed a standard approach for the descrip-
tion, standardization and monitoring of the intervention
to enable reliable assessment of outcome from this type
of study and, importantly, reproducibility of an interven-
tion by surgeons in their clinical practice. In this review,
only one study46 had monitoring of technique by a senior
surgeon to allow consistency of mesh placement.
It is plausible that different biological meshes may have
varying failure rates, degrees of immunogenicity, biocom-
patibility and risk profiles60. In a rat study61 of 85 laparo-
scopic ventral hernia repairs, Strattice™ and Parietex™
(Covidien Surgical, Dublin, Ireland) were seen to grow a
newmesothelial layer on their visceral side, whereas micro-
scopic degradation and new collagen formation were seen
in the Surgisis® group. In a mouse model of 135 mice with
peritonitis, XCM BIOLOGIC® (LifeCell, KCI, Branch-
burg, New Jersey, USA) and Permacol™ showed better
incorporation than Strattice™, whereas Strattice™ had
fewer strong adhesions62. More accurate information from
human studies may allow improved selection of mesh for
patients in future clinical practice.
The direct advantages of biological mesh remain
unproven in widespread practice. First, the long-term
durability of biological grafts used for complex abdominal
wall reconstruction has been disappointing36,43. Rosen and
co-workers43 reported the overall hernia recurrence rate
as 31 per cent over a mean follow-up of 21⋅7 (range 1–74)
months, and estimated the 3-year recurrence-free survival
rate to be 51 per cent. Second, implementation and use of
biological mesh in clinical practice depend on the cost, as
biological meshes can be up to ten times more expensive
than synthetic ones17,63. Totten et al.64 demonstrated that
use of biological mesh for hernia repair can cost $21 000
(€17 100; exchange rate 20 April 2018) in comparison with
synthetic mesh, which costs $7100 (€5780) for minimal
improvement in surgical outcomes such as SSI.
With high costs of abdominal wall reconstruction using
biological meshes and limited long-term data, there has
been emerging interest in the use of long-term absorbable
synthetic materials. These biosynthetic meshes are a clin-
ical alternative to biological meshes and are significantly
cheaper. A prospective longitudinal study by Rosen and
colleagues65, evaluating the use of GORE® BIO-A®
(W. L. Gore, Newark, Delaware, USA) biosynthetic mesh
in CDC class II–IV wounds, demonstrated an SSI rate of
18 per cent and a hernia recurrence rate of 17 per cent at
24months. In contrast, the RICH trial36, which evaluated
CDC II–IV wounds with biological mesh, had an SSI
rate of 66 per cent and recurrence rate of 28 per cent
at 24months. Although this evidence with biosynthetic
meshes is promising, any superiority over biological mesh
in clean, clean-contaminated, contaminated or infected
wounds remains to be tested in RCTs.
Several ongoing cohort studies and RCTs will improve
the evidence base, although they predominantly involve
elective patients. Only three studies include both elective
and emergency patients for prophylaxis. Future studies in
high-risk patients (such as those undergoing emergency
surgery, with active sepsis or high BMI) will establish new
indications for biological mesh, with potentially greater
benefit in these patients. Preventing the need for reoper-
ation in high-risk groups is likely to provide even greater
cost savings to health services.
There are weaknesses to this study. Assessment of quality
using the GRADE tool is subjective, although this was
overcome by discussion between the two authors involved
in assessing grade of evidence, and resolving disagreement
by re-examining the relevant article until consensus had
been achieved. Nevertheless, this scoring system is used
widely for assessing strength of evidence in the literature20.
Biosynthetic resorbable meshes and patients undergoing
bridged repairs were not included in the study, as they
represent a clinically separate group and are likely to have a
different stage of innovation due to timing of introduction.
The evidence base for biological mesh in this clinical
context is limited and evolving. Better reporting and quality
control of surgical techniques is needed and, although new
trial results over the next decade will improve the evidence
base, more trials in emergency and contaminated settings
are required.
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